Biocon, Mylan get USFDA nod for pegfilgrastim drug substance licence

This additional approval of its new manufacturing facility for pegfilgrastim in Bengaluru will enable the biotechnology major to enable its arm Biocon Biologics and Mylan to scale up capacity multi-fold and address the growing market opportunities in US and other global markets.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news